Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of XEN1101 in Healthy Subjects
NCT03340220Phase 1Completed
- Sponsor
- Xenon Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of azetukalner in epilepsy (7 arms), sponsored by Xenon Pharmaceuticals. Primary endpoints: Number of Participants with Adverse Events, Resting electrocardiogram and 4 more. Started Nov 2017; status: completed.
02
Drugs
azetukalner
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03340220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340220.